1. Home
  2. NRIX vs CTRI Comparison

NRIX vs CTRI Comparison

Compare NRIX & CTRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.18

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Centuri Holdings Inc.

CTRI

Centuri Holdings Inc.

HOLD

Current Price

$26.58

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
CTRI
Founded
2009
1909
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
NRIX
CTRI
Price
$19.18
$26.58
Analyst Decision
Strong Buy
Hold
Analyst Count
13
4
Target Price
$26.77
$23.25
AVG Volume (30 Days)
1.9M
2.1M
Earning Date
01-27-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$83,687,000.00
$2,841,255,000.00
Revenue This Year
$58.38
$10.61
Revenue Next Year
N/A
$9.02
P/E Ratio
N/A
$1,052.83
Revenue Growth
48.32
9.89
52 Week Low
$8.18
$14.46
52 Week High
$22.50
$27.50

Technical Indicators

Market Signals
Indicator
NRIX
CTRI
Relative Strength Index (RSI) 66.53 71.43
Support Level $19.02 $25.10
Resistance Level $22.50 $27.50
Average True Range (ATR) 1.18 1.04
MACD 0.10 0.44
Stochastic Oscillator 52.01 88.17

Price Performance

Historical Comparison
NRIX
CTRI

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About CTRI Centuri Holdings Inc.

Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. It operates under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.

Share on Social Networks: